CD8A and neoplasm: Adding anti-PD1 treatment to the tipifarnib/alpelisib combination further prolonged progression-free survival in tumor-bearing mice.<h4>Conclusion</h4>These findings underscore the critical role of antitumor immunity, particularly CD8<sup>+</sup>T cell activity, in the efficacy of tipifarnib alone and in combination with alpelisib.